Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CGEN
stocks logo

CGEN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.62M
+10.1%
-0.077
+10.71%
1.25M
-45.27%
-0.075
-6.25%
1.25M
-0.56%
-0.075
-6.25%
Estimates Revision
The market is revising Upward the revenue expectations for Compugen Ltd. (CGEN) for FY2025, with the revenue forecasts being adjusted by 9.03% over the past three months. During the same period, the stock price has changed by 12.59%.
Revenue Estimates for FY2025
Revise Upward
up Image
+9.03%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-8.66%
In Past 3 Month
Stock Price
Go Up
up Image
+12.59%
In Past 3 Month
Wall Street analysts forecast CGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGEN is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast CGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGEN is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.610
sliders
Low
4.00
Averages
4.00
High
4.00
Current: 1.610
sliders
Low
4.00
Averages
4.00
High
4.00
no data image
No Data

Valuation Metrics

The current forward P/E ratio for Compugen Ltd (CGEN.O) is -5.24, compared to its 5-year average forward P/E of -27.98. For a more detailed relative valuation and DCF analysis to assess Compugen Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-27.98
Current PE
-5.24
Overvalued PE
19.00
Undervalued PE
-74.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.53
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.67
Undervalued EV/EBITDA
-6.74

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
39.36
Current PS
0.00
Overvalued PS
161.12
Undervalued PS
-82.39
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CGEN News & Events

Events Timeline

(ET)
2025-11-10
07:15:47
Compugen announces Q3 earnings per share of 7 cents, below consensus estimate of 9 cents.
select
2025-08-06 (ET)
2025-08-06
07:22:53
Compugen reports Q2 EPS (8c), consensus (9c)
select
2025-07-21 (ET)
2025-07-21
07:03:29
Compugen begins dosing in ovarian cancer trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-10PRnewswire
Compugen Reports Third Quarter 2025 Results

  • Clinical Trials Update: Compugen presented Phase 1 data for COM701 at ESMO 2025, showing promising results in platinum-resistant ovarian cancer, and is currently enrolling patients in the MAIA-ovarian platform trial with interim analysis expected in Q1 2027.

  • Partnership Developments: AstraZeneca shared positive results for rilvegostomig in NSCLC and bladder cancer at ESMO 2025, highlighting the potential of their Fc-reduced anti-TIGIT antibody format, which may improve efficacy and safety.

  • Financial Position: Compugen reported a cash position of approximately $86.1 million as of September 30, 2025, with expectations to fund operations into Q3 2027, despite a net loss of about $6.98 million for the third quarter.

  • Pipeline and Future Prospects: The company is advancing its immuno-oncology pipeline, including GS-0321, an anti-IL-18 binding protein antibody licensed to Gilead, and aims to leverage its AI/ML platform for novel cancer therapies.

[object Object]
Preview
1.0
11-04PRnewswire
Compugen to Participate in Stifel 2025 Healthcare Conference

  • Company Announcement: Compugen Ltd. will participate in a fireside chat at the Stifel 2025 Healthcare Conference in New York City on November 11, 2025, from 3:20-3:50 PM ET, with a live webcast available on their website.

  • Company Overview: Compugen is a clinical-stage cancer immunotherapy company that uses AI/ML for drug target discovery, with two proprietary product candidates in Phase 1 development and a bispecific antibody in Phase 3 development through a partnership with AstraZeneca.

[object Object]
Preview
3.0
10-27PRnewswire
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025

  • Upcoming Financial Results: Compugen Ltd. will release its third quarter 2025 financial results on November 10, 2025, before U.S. markets open, followed by a conference call at 8:30 AM ET.

  • Company Overview: Compugen is a clinical-stage cancer immunotherapy company utilizing AI/ML for drug target discovery, with two proprietary candidates in Phase 1 development and a bispecific antibody in Phase 3 development through a partnership with AstraZeneca.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Compugen Ltd (CGEN) stock price today?

The current price of CGEN is 1.61 USD — it has increased 2.55 % in the last trading day.

arrow icon

What is Compugen Ltd (CGEN)'s business?

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

arrow icon

What is the price predicton of CGEN Stock?

Wall Street analysts forecast CGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGEN is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Compugen Ltd (CGEN)'s revenue for the last quarter?

Compugen Ltd revenue for the last quarter amounts to 1.89M USD, decreased -88.96 % YoY.

arrow icon

What is Compugen Ltd (CGEN)'s earnings per share (EPS) for the last quarter?

Compugen Ltd. EPS for the last quarter amounts to -0.07 USD, decreased -800.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Compugen Ltd (CGEN)'s fundamentals?

The market is revising Upward the revenue expectations for Compugen Ltd. (CGEN) for FY2025, with the revenue forecasts being adjusted by 9.03% over the past three months. During the same period, the stock price has changed by 12.59%.
arrow icon

How many employees does Compugen Ltd (CGEN). have?

Compugen Ltd (CGEN) has 74 emplpoyees as of December 05 2025.

arrow icon

What is Compugen Ltd (CGEN) market cap?

Today CGEN has the market capitalization of 149.66M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free